Last reviewed · How we verify
GC1008
At a glance
| Generic name | GC1008 |
|---|---|
| Also known as | IgG4 kappa monoclonal antibody, fresolimumab |
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta (PHASE1)
- Safety and Imaging Study of GC1008 in Glioma (PHASE2)
- SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer (PHASE1, PHASE2)
- Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (PHASE2)
- Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) (PHASE1)
- Fresolimumab and Radiotherapy in Metastatic Breast Cancer (PHASE2)
- A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) (PHASE2)
- Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |